These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15626585)

  • 61. Comparative in vitro dissolution study of carbamazepine immediate-release products using the USP paddles method and the flow-through cell system.
    Medina JR; Salazar DK; Hurtado M; Cortés AR; Domínguez-Ramírez AM
    Saudi Pharm J; 2014 Apr; 22(2):141-7. PubMed ID: 24648826
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Biorelevant media to simulate fluids in the ascending colon of humans and their usefulness in predicting intracolonic drug solubility.
    Vertzoni M; Diakidou A; Chatzilias M; Söderlind E; Abrahamsson B; Dressman JB; Reppas C
    Pharm Res; 2010 Oct; 27(10):2187-96. PubMed ID: 20676736
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The application of modified flow-through cell apparatus for the assessment of chlorhexidine dihydrochloride release from lozenges containing sorbitol.
    Musial W; Mielck JB
    AAPS PharmSciTech; 2009; 10(3):1048-57. PubMed ID: 19669894
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults.
    Diakidou A; Vertzoni M; Goumas K; Söderlind E; Abrahamsson B; Dressman J; Reppas C
    Pharm Res; 2009 Sep; 26(9):2141-51. PubMed ID: 19572187
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of dissolution profiles for sustained release resinates of BCS class I drugs using USP apparatus 2 and 4: a technical note.
    Prabhu NB; Marathe AS; Jain S; Singh PP; Sawant K; Rao L; Amin PD
    AAPS PharmSciTech; 2008; 9(3):769-73. PubMed ID: 18563575
    [No Abstract]   [Full Text] [Related]  

  • 66. In vivo performance of an oral MR matrix tablet formulation in the beagle dog in the fed and fasted state: assessment of mechanical weakness.
    McInnes F; Clear N; Humphrey M; Stevens HN
    Pharm Res; 2008 May; 25(5):1075-84. PubMed ID: 17917709
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies.
    Kalantzi L; Goumas K; Kalioras V; Abrahamsson B; Dressman JB; Reppas C
    Pharm Res; 2006 Jan; 23(1):165-76. PubMed ID: 16308672
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Development of monolithic osmotic pump tablet system for isosorbide-5-mononitrate delivery and evaluation of it in vitro and in vivo.
    Duan X; Liu Q; Zhang Y; Bi K; Chen X; Wang Y; Luo G
    Drug Dev Ind Pharm; 2009 Apr; 35(4):499-507. PubMed ID: 18979308
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.
    Kosoglou T; Patrick JE; Cohen A; Radwanski E; Christopher D; Affrime MB
    Clin Ther; 1995; 17(2):241-51. PubMed ID: 7614524
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet.
    Kosoglou T; Kazierad DJ; Schentag JJ; Patrick JE; Heimark L; Radwanski E; Christopher D; Flannery BE; Affrime MB
    J Clin Pharmacol; 1995 Feb; 35(2):151-8. PubMed ID: 7751425
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group.
    Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE
    Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515
    [TBL] [Abstract][Full Text] [Related]  

  • 72. In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis.
    Fotaki N; Symillides M; Reppas C
    Eur J Pharm Sci; 2005 Jan; 24(1):115-22. PubMed ID: 15626585
    [TBL] [Abstract][Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.